Dena Kia

Dena Kia is an associate in the firm’s Complex Litigation & Dispute Resolution practice. She focuses her practice on complex commercial litigation and government and internal investigations. She is a member of the firm’s Government Investigations, Enforcement & White Collar Defense, and Digital Currency & Blockchain Technology groups. Dena also maintains an active pro bono practice, including matters involving veterans, asylum, and guardianship. She joined Goodwin in 2022.

 Dena’s recent work includes:

• Representing a director in connection with a DOJ fraud investigation
• Representing a private equity firm in connection with a DOJ investigation involving a potential acquisition target
• Representing a former CEO and CFO in connection with an SEC investigation into the company’s debt-for-equity transactions
• Representing an AI company in connection with an False Claims Act investigation relating to cybersecurity compliance under a government contract
• Representing a digital asset infrastructure company in conducting an internal investigation and compliance review relating to its business operations
• Representing a digital asset company in securities class action litigations relating to its digital asset offerings and trading activity
• Representing a service provider to a DeFi protocol in litigation concerning its platform features
• Representing a large national bank in multidistrict class action litigation alleging violations of the Electronic Funds Transfer Act and state unfair competition laws
• Representing a cyber risk management firm in trade secret litigation
• Representing a medical device company in trade secret litigation
• Representing prominent legal scholars in connection with an amicus brief filed in the Supreme Court of the United States and various U.S. Courts of Appeals

• Co-Author, “Digital Currency & Blockchain Quarterly Litigation Update,” Goodwin Insight, 2026
• Co-Author, “Digital Currency & Blockchain Quarterly Litigation Update,” Goodwin Insight, 2025
• Contact, “Securities Litigation Against Life Sciences Companies 2023 Year in Review,” Goodwin Insight, 2023